Evidence map›Paper›PMID 37587497›Full record

ReviewHuman genomics2023

Determining the utility of diagnostic genomics: a conceptual framework.

Andrew Mallett, Zornitza Stark, Zoe Fehlberg, Stephanie Best, Ilias Goranitis

Open access · goldAbstract readReview
In one paragraph

Review in Human genomics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Genetic Testing of Movements Disorders: A Review of Clinical Utility.Tremor and other hyperkinetic movements (New York, N.Y.) · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Andrew MallettAustralian Genomics, Murdoch Children's Research Institute, Melbourne, VIC, Australia. Andrew.mallett@health.qld.gov.au.
Zornitza StarkAustralian Genomics, Murdoch Children's Research Institute, Melbourne, VIC, Australia.
Zoe FehlbergAustralian Genomics, Murdoch Children's Research Institute, Melbourne, VIC, Australia.
Stephanie BestAustralian Genomics, Murdoch Children's Research Institute, Melbourne, VIC, Australia.
Ilias GoranitisAustralian Genomics, Murdoch Children's Research Institute, Melbourne, VIC, Australia.
Victorian Clinical Genetics Services · AUMurdoch Children's Research Institute · AUUniversity of Melbourne · AUVictorian Comprehensive Cancer Centre · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDiagnostic efficacy is now well established for diagnostic genomic testing in rare disease. Assessment of overall utility is emerging as a key next step, however ambiguity in the conceptualisation and measurement of utility has impeded its assessment in a comprehensive manner. We propose a conceptual framework to approach determining the broader utility of diagnostic genomics encompassing patients, families, clinicians, health services and health systems to assist future evidence generation and funding decisions. BODY: Building upon previous work, our framework posits that utility of diagnostic genomics consists of three dimensions: the domain or type and extent of utility (what), the relationship and perspective of utility (who), and the time horizon of utility (when). Across the description, assessment, and summation of these three proposed dimensions of utility, one could potentially triangulate a singular point of utility axes of type, relationship, and time. Collectively, the multiple different points of individual utility might be inferred to relate to a concept of aggregate utility.

conclusionThis ontological framework requires retrospective and prospective application to enable refinement and validation. Moving forward our framework, and others which have preceded it, promote a better characterisation and description of genomic utility to inform decision-making and optimise the benefits of genomic diagnostic testing.

Indexed as

GenomicsRare DiseasesHumansRetrospective StudiesDiagnostic genomicsFrameworkImplementationOntologyUtility

Identifiers

PMID37587497
PMCPMC10433656
OpenAlexW4385878288

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.